Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
At $298, the test guides PlexusDx providers in personalizing not just timing but also compound selection and dose escalation strategy
TRIUMPH-4 confirmed: Retatrutide 28.7% weight loss in Phase 3 (December 2025) final data, not preliminary TRIUMPH-1 confirmed (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients without diabetes pivotal trial met all primary endpoints TRANSCEND-T2D-1 confirmed (June 2026): -2.0% HbA1c and 16.8% weight loss in type 2 diabetes patients a separate diabetes-specific Phase 3 program Filing timeline updated: Eli Lilly will submit a Biologics License Application (BLA) not an NDA, since retatrutide is a biologic expected Q1 2027 (shifted from the previously estimated Q4 2026) Availability updated: Retatrutide remains investigational
Genetic insights from the PlexusDx Precision Peptide Genetic Test can also inform your provider's recommendations, as variants in genes like GLP1R rs6923761 may influence how quickly your body processes and responds to dosing intervals
Can you lose weight while on Zoloft
Two free courses are included
